Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

COVID-19 survivors tend to have a roughly tenfold increase in protection against the virus, according to a government-funded study published Wednesday.

Why it matters: There have been some documented cases of reinfection leading to concern survivors don't gain any immunity. While there remain questions on how much or how long immunity lasts and what the impact of variants will be, this large set of observational data bolsters evidence there's some protection.

The latest: The study, published in JAMA Internal Medicine, examined commercial SARS-CoV-2 antibody test data from 3.2 million U.S. patients from Jan. 1 and Aug. 23, 2020.

  • Out of those who had tested antibody-negative initially and were later tested for active infection, they found 3% were positive for SARS-CoV-2 90 or more days later.
  • Out of those who were antibody-positive initially and were later tested for active infection, they found only 0.3% were positive for SARS-CoV-2 90 or more days later.
  • "There's a tenfold decrease, which is essentially a 90% reduction in risk for people who are antibody positive," says Doug Lowy, co-author and deputy director of the National Cancer Institute, which conducted the study.
  • "It's something that has been hypothesized for a long time, but our study is by far the largest study to look at this, especially in the United States," Lowy says.

Caveat: Because the study examines real-time data and was not done in a clinical trial setting, there are could be "confounders," or distorting factors, that affect results, Lowy points out. This means the tenfold protection is a rough average — in actuality, "maybe it's a threefold difference, and maybe it's a twentyfold difference."

  • However, the results do closely match another recent NEJM study from the U.K. that also found a roughly tenfold difference, he says.

What they're saying: Jennifer Juno, a senior research fellow at the University of Melbourne's Doherty Institute who was not part of the study, says "several studies now suggest that prior infection does indeed provide protection against re-infection, as we would expect."

  • "The key questions we need to address now include understanding the duration of this protection, and the specific immune responses that are most strongly associated with protection," she says.

Juno co-authored a different paper published last week in Nature Communications looking at the level of antibodies in people over a four-month period after infection. They found:

  • People tend to have strong neutralizing antibodies initially that rapidly decline by about 50% within 55 days, but that decline slows and plateaus.
  • And then other immune system actors pick up. The level of B cells that produce antibodies to the coronavirus spike protein increased over time in their study participants, rather than declined, Juno says.
  • "This is encouraging news, as it suggests that the immune system is generating a robust memory response to infection, which is likely to play a role in providing some protection from reinfection," she adds.

The big picture: Vaccination is still highly recommended for those who've been infected before, both Lowy and Juno say.

  • "Early studies suggest that individuals who were previously infected show substantial boosting of their antibody levels after receiving one dose of a COVID vaccine, which points to a great benefit of receiving the vaccine even if you have been previously infected," Juno says.

Go deeper: The hurdles we face before reaching herd immunity

Go deeper

Feb 25, 2021 - Health

Pfizer begins study on 3rd vaccine dose as booster shot against new variants

Photo: Pete Bannan/MediaNews Group/Daily Local News via Getty Images

Pfizer and BioNTech on Thursday announced they have launched a study to evaluate whether a third dose of their COVID-19 vaccine can protect against new variants of the virus.

Why it matters: Vaccine makers are racing to find effective ways to fight more infectious virus variants. There is no evidence that the current vaccines are not effective against the new variants, but companies are looking for ways to adapt to new mutations in case it becomes necessary.

New coronavirus cases fall by 20%

Expand chart
Data: The COVID Tracking Project, state health departments; Map: Andrew Witherspoon/Axios

New coronavirus infections continued their sharp decline over the past week, and are now back down to pre-Thanksgiving levels.

The big picture: Given the U.S.’ experience over the past year, it can be hard to trust anything that looks like good news, without fearing that another shoe is about to drop. But the U.S. really is doing something right lately. Cases are way down, vaccinations are way up, and that’s going to save a lot of lives.

Caitlin Owens, author of Vitals
Feb 25, 2021 - Health

Republicans are least likely to want the coronavirus vaccine

Reproduced from Civiqs; Chart: Axios Visuals

Americans of all ages, education levels, genders, races and political parties say they're more likely than not to get the coronavirus vaccine — except Republicans.

Why it matters: Vaccine hesitancy is higher among white Republicans than any other demographic group, and it hasn't been improving much as the vaccination effort continues, according to Civiqs polling.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!